vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and LXP Industrial Trust (LXP). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $86.7M, roughly 1.6× LXP Industrial Trust). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 33.2%, a 2.3% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -14.0%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 0.3%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
LXP Industrial Trust is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality industrial real estate assets, primarily distribution centers, logistics facilities, and light industrial properties across key markets in the United States. Its tenant base covers e-commerce, third-party logistics, and advanced manufacturing sectors, delivering stable long-term returns for its investors.
ADMA vs LXP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $86.7M |
| Net Profit | $49.4M | $28.8M |
| Gross Margin | 63.8% | 81.5% |
| Operating Margin | 45.1% | 34.6% |
| Net Margin | 35.5% | 33.2% |
| Revenue YoY | 18.4% | -14.0% |
| Net Profit YoY | -55.9% | — |
| EPS (diluted) | $0.20 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $86.7M | ||
| Q3 25 | $134.2M | $86.9M | ||
| Q2 25 | $122.0M | $87.7M | ||
| Q1 25 | $114.8M | $88.9M | ||
| Q4 24 | $117.5M | $100.9M | ||
| Q3 24 | $119.8M | $85.6M | ||
| Q2 24 | $107.2M | $85.8M | ||
| Q1 24 | $81.9M | $86.3M |
| Q4 25 | $49.4M | $28.8M | ||
| Q3 25 | $36.4M | $36.3M | ||
| Q2 25 | $34.2M | $29.1M | ||
| Q1 25 | $26.9M | $19.0M | ||
| Q4 24 | $111.9M | — | ||
| Q3 24 | $35.9M | $6.3M | ||
| Q2 24 | $32.1M | $5.4M | ||
| Q1 24 | $17.8M | $-269.0K |
| Q4 25 | 63.8% | 81.5% | ||
| Q3 25 | 56.3% | 82.3% | ||
| Q2 25 | 55.1% | 81.9% | ||
| Q1 25 | 53.2% | 80.7% | ||
| Q4 24 | 53.9% | 85.3% | ||
| Q3 24 | 49.8% | 82.5% | ||
| Q2 24 | 53.6% | 82.0% | ||
| Q1 24 | 47.8% | 82.4% |
| Q4 25 | 45.1% | 34.6% | ||
| Q3 25 | 38.0% | 50.4% | ||
| Q2 25 | 35.1% | 33.7% | ||
| Q1 25 | 30.4% | 21.8% | ||
| Q4 24 | 32.6% | — | ||
| Q3 24 | 33.1% | 7.9% | ||
| Q2 24 | 36.6% | 6.9% | ||
| Q1 24 | 26.7% | 1.0% |
| Q4 25 | 35.5% | 33.2% | ||
| Q3 25 | 27.1% | 41.7% | ||
| Q2 25 | 28.1% | 33.2% | ||
| Q1 25 | 23.4% | 21.4% | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | 7.4% | ||
| Q2 24 | 29.9% | 6.3% | ||
| Q1 24 | 21.7% | -0.3% |
| Q4 25 | $0.20 | — | ||
| Q3 25 | $0.15 | $0.12 | ||
| Q2 25 | $0.14 | $0.09 | ||
| Q1 25 | $0.11 | $0.06 | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.15 | $0.02 | ||
| Q2 24 | $0.13 | $0.01 | ||
| Q1 24 | $0.08 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $170.4M |
| Total DebtLower is stronger | $72.1M | $1.4B |
| Stockholders' EquityBook value | $477.3M | $2.0B |
| Total Assets | $624.2M | $3.5B |
| Debt / EquityLower = less leverage | 0.15× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $170.4M | ||
| Q3 25 | $61.4M | $229.7M | ||
| Q2 25 | $90.3M | $71.0M | ||
| Q1 25 | $71.6M | $70.9M | ||
| Q4 24 | $103.1M | $101.8M | ||
| Q3 24 | $86.7M | $55.0M | ||
| Q2 24 | $88.2M | $48.7M | ||
| Q1 24 | $45.3M | $293.8M |
| Q4 25 | $72.1M | $1.4B | ||
| Q3 25 | $72.4M | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | $72.3M | $1.6B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $2.0B | ||
| Q3 25 | $431.2M | $2.1B | ||
| Q2 25 | $398.3M | $2.1B | ||
| Q1 25 | $373.4M | $2.1B | ||
| Q4 24 | $349.0M | $2.1B | ||
| Q3 24 | $231.9M | $2.1B | ||
| Q2 24 | $188.3M | $2.1B | ||
| Q1 24 | $153.7M | $2.2B |
| Q4 25 | $624.2M | $3.5B | ||
| Q3 25 | $568.7M | $3.7B | ||
| Q2 25 | $558.4M | $3.7B | ||
| Q1 25 | $510.6M | $3.8B | ||
| Q4 24 | $488.7M | $3.8B | ||
| Q3 24 | $390.6M | $3.9B | ||
| Q2 24 | $376.4M | $3.9B | ||
| Q1 24 | $350.9M | $4.2B |
| Q4 25 | 0.15× | 0.66× | ||
| Q3 25 | 0.17× | 0.72× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 0.21× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $188.7M |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | 6.56× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $188.7M | ||
| Q3 25 | $13.3M | $63.5M | ||
| Q2 25 | $21.1M | $44.3M | ||
| Q1 25 | $-19.7M | $39.0M | ||
| Q4 24 | $50.2M | $211.2M | ||
| Q3 24 | $25.0M | $64.6M | ||
| Q2 24 | $45.6M | $38.5M | ||
| Q1 24 | $-2.2M | $38.9M |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $24.0M | — | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $-4.6M | — |
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 40.7% | — | ||
| Q1 24 | -5.6% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 2.9% | — |
| Q4 25 | 0.72× | 6.56× | ||
| Q3 25 | 0.36× | 1.75× | ||
| Q2 25 | 0.62× | 1.52× | ||
| Q1 25 | -0.73× | 2.05× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 10.18× | ||
| Q2 24 | 1.42× | 7.09× | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
LXP
Segment breakdown not available.
